These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11455683)

  • 1. In vivo susceptibility of Mycobacterium ulcerans to KRM-1648, a new benzoxazinorifamycin, in comparison with rifampicin. Anti-mycobacterial activity of KRM-1648.
    Dhople AM
    Arzneimittelforschung; 2001; 51(6):501-5. PubMed ID: 11455683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal action at low doses of a new rifamycin derivative, 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl) benzoxazinorifamycin (KRM-1648) on Mycobacterium leprae inoculated into footpads of nude mice.
    Gidoh M; Tsutsumi S; Yamane T; Yamashita K; Hosoe K; Hidaka T
    Lepr Rev; 1992 Dec; 63(4):319-28. PubMed ID: 1479871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
    Dhople AM
    Int J Antimicrob Agents; 2001 Jan; 17(1):57-61. PubMed ID: 11137650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of inhibitory effect of rifalazil and rifampicin against Mycobacterium ulcerans infection induced in mice].
    Nakanaga K; Saito H; Ishii N; Goto M
    Kekkaku; 2004 May; 79(5):333-9. PubMed ID: 15211873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
    Tomioka H; Saito H
    Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice.
    Dhople AM; Namba K
    J Chemother; 2003 Feb; 15(1):47-52. PubMed ID: 12678414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis].
    Sato K; Tomioka H; Saito H; Kawahara S; Hidaka T
    Kekkaku; 1996 Aug; 71(8):459-64. PubMed ID: 8831191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo antileprosy activity of the newly synthesized benzoxazinorifamycin, KRM-1648.
    Tomioka H; Saito H
    Int J Lepr Other Mycobact Dis; 1993 Jun; 61(2):255-8. PubMed ID: 8371034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
    Tomioka H
    Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.
    Mor N; Simon B; Heifets L
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1482-5. PubMed ID: 8726023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with glycyrrhizin against Mycobacterium avium complex infection in mice].
    Shimizu T; Tomioka H; Sato K; Akaki T; Ogasawara K; Kawahara S
    Kekkaku; 1999 Aug; 74(8):617-21. PubMed ID: 10487030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo activities of novel benzoxazinorifamycins against Mycobacterium leprae.
    Dhople AM; Ibanez MA
    Indian J Lepr; 1995; 67(4):375-82. PubMed ID: 8849914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of half-sized secretory leukocyte protease inhibitor and Chinese traditional medicines, yokuinin and mao-bushi-saishin-to, on therapeutic efficacies of benzoxazinorifamycin KRM-1648 against Mycobacterium avium complex infection induced in mice].
    Sato K; Shimizu T; Tomioka H; Kawahara S
    Kekkaku; 1998 Aug; 73(8):501-6. PubMed ID: 9780605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages.
    Suzuki K; Tsuyuguchi K; Matsumoto H; Yamamoto T; Hashimoto T; Tanaka E; Amitani R; Kuze F
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):460-7. PubMed ID: 9441102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis.
    Hirata T; Saito H; Tomioka H; Sato K; Jidoi J; Hosoe K; Hidaka T
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2295-303. PubMed ID: 8619585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1). A study on the efficacy of short course treatment with the intratracheal and intravenous infection model].
    Doi N
    Kekkaku; 1998 Feb; 73(2):53-64. PubMed ID: 9545697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo activities of KRM-1648, a newly synthesized benzoxazinorifamycin, against Mycobacterium marinum.
    Yamamoto Y; Saito H; Tomioka H; Sato K; Yamane T; Yamashita K; Hosoe K; Hidaka T
    Zentralbl Bakteriol; 1992 Jul; 277(2):204-9. PubMed ID: 1520979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice].
    Akaki T; Sato K; Shimizu T; Tomioka H; Kawahara S
    Kekkaku; 1997 Aug; 72(8):491-7. PubMed ID: 9293712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
    Sato K; Tomioka H
    Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.
    Ji B; Chauffour A; Robert J; Lefrançois S; Jarlier V
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3737-9. PubMed ID: 17664316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.